LEWISTON, New York, November 22 /PRNewswire-FirstCall/ -- LAM Pharmaceutical, Corp. , a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced today the re-launch of its patented proprietary Sexual Dysfunction Treatment Products, which are based on LAM's novel IPM Ionic Polymer Matrix. Following the cancellation for non-payment of the license to Ixora Biomedical, LAM has granted a worldwide license (with the notable exception of China) for the sexual dysfunction treatment product group to the Cayman Islands based international marketing company Exoris Inc. The first product marketed under the Exoris brand will be LAM's patented female sexual enhancement gel.
Mr. Howard Deverett, CEO of Exoris Inc. stated, "In all my years of marketing products and services, marketing the LAM female sexual enhancement product will be most challenging. We will be utilizing infomercials and internet marketing to develop Exoris into a leading brand within the next two years."
Mr. Joseph T. Slechta, President and Chief Executive Officer of LAM noted, "We are very excited about this new opportunity. LAM is confident that Exoris' financial resources and global marketing expertise will translate into significant licensing revenue for LAM." Mr. Slechta concluded, "We will do our utmost to assist Exoris to meet its sales commencement target date of April 2006."
About LAM Pharmaceutical, Corp.
For more information about LAM Pharmaceutical, Corp., please see our web site at www.lampharm.com .
About Exoris Inc.
Exoris Inc. is an international distribution company with headquarters in the Cayman Islands and a main operation facility in Florida. Exoris' primary business focus is to distribute LAM sexual dysfunction treatment products.
Statements in this press release regarding our business which are not historical facts are "forward-looking statements" that involve risks and uncertainties which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, but are not limited to uncertainties relating to the need for additional funds and corporate partners, product liability, dependence on third parties for manufacturing and marketing, the early stage of products being marketed or under development, patent risk and competition.
L.A.M. Ionic Polymer Matrix(TM), L.A.M. IPM(TM) and IPM Wound Gel(TM) are trademarks of L.A.M. Pharmaceutical, Corp.
L.A.M. IPM Wound Gel(TM) is protected by one or more of the following patents: 5,897,880; 6,120,804; 6,007,843; 6,063,405.
Stephanie Carrington (Investors/Media)
The Ruth Group
LAM Pharmaceutical, Corp.